Feature | HRS | August 23, 2022 | By Lars Thording, PhD

Post-Pandemic, the Conversations Have Lost Relevance

Key Takeaways from the 2022 Heart Rhythm Society Meeting

Key Takeaways from the 2019 Heart Rhythm Society Meeting

Hospitals in the U.S. are suffering under a debilitating post-pandemic financial and operational trauma. Ascension posted an almost $900 million loss in Q1 of 2022, down from net income of $957.32 million in Q1 of 2021. Kaiser Permanente posted a loss closer to $1 billion, down from net income of $2 billion in the same quarter last year. Labor costs are going through the roof as hospitals battle labor shortages and a substantial increase in the use of contract workers; medical devices and other supplies are becoming more expensive as suppliers adjust their prices to account for their supply chain challenges; and a whole host of systemic challenges have emerged from the pandemic, impacting everything from service line profitability to sustainable financial structures. At the same time, hospital systems still have to make good for the extra expenses they incurred for testing, care and other COVID-related expenses. 

More Discussion Needed on Cost-savings Solutions

On this backdrop, you would expect that healthcare science and technology conferences in 2022 would pivot from a focus on more expensive treatment discussions to a focus on solutions that drive cost savings. After all, the physicians at these conferences quite simply won’t have a lab to work in unless the cost of procedures goes down. Unfortunately, at least at Heart Rhythm Society’s (HRS) 2022 Scientific Sessions, this was not the case. Rather, it was more of the same as prior years, with large, multinational technology companies launching new, more expensive devices, and physician leaders speaking into a great echo chamber populated by other physician leaders about new treatment approaches that they see rendering better results. Since their research is mostly funded by the same technology companies that profit from the adoption of new treatment approaches, the issue of costs was simply not addressed.

There were, of course, new announcements from the large technology companies. Biosense Webster promoted the Octaray and Optrell mapping catheters and the NuVision 4D ultrasound catheter, Abbott focused on its EnSite X mapping system, and Boston Scientific promoted Farapulse, the leading pulsed field ablation (PFA) system Boston acquired last year. PFA is poised to become a small revolution in atrial fibrillation and other arrhythmia treatments, and several other companies, including Galaxy Medical, were at HRS to show their progress in the area.

The pace of new technology launches in electrophysiology is rapid, and Heart Rhythm Society is the place to see the newest devices and systems. However, we’ve been seeing signs in recent years that hospitals and physicians are less eager than usual to simply pick up new devices just because they are new. We saw it first with the SoundStar diagnostic ultrasound catheter from Biosense Webster. It was launched with functionality and technical features that clearly differentiated it from the predecessor device, the 2D AcuNav. However, at many of the more advanced health systems, physicians did not simply switch from using AcuNav to SoundStar; although the SoundStar could do more, apparently many found this made no difference in patient outcomes.

The Octaray, launched last year, provides another example of a solution in search of a problem: The Octaray was launched as a next-generation Pentaray — essentially providing extra electrodes on three extra “arms” to make mapping faster and more detailed. Biosense Webster appears to have struggled with adoption as physicians increasingly question whether new technology will truly improve their practices.

The trend appears it may continue. This year, Biosense Webster launched the Optrell mapping catheter, which is quite similar to the Abbott Advisor HD Grid. While the company presumably hopes this technology will alter physician preferences, they might find these customers again questioning the value for the money.

A Call to Action for Hospitals

Physicians are right to be questioning value when it comes to new technology and whether it truly improves patient outcomes. In fact, this is precisely the kind of thinking that is needed in electrophysiology at a time when hospitals and healthcare in general need to focus on the economics of healthcare. It would be helpful if the large medtech companies listened and built procedure economics into their launch strategies. Likewise, Heart Rhythm Society might benefit from revisiting format and participation to deliver on its “mission to improve the care of patients by promoting research, education, and optimal healthcare policies and standards.”

In a May 8 Wall Street Journal article titled “Hospitals Look to Raise Treatment Costs as Nurses’ Salaries Increase,” the reporter describes how major hospital systems (HCA, UHS) are translating higher nurse salaries directly to increasing procedure prices (15% vs. 3% in a normal year) in their discussions with insurance companies and employers. This will translate directly to higher patient premiums. In other words, consumers are poised to pay for the post-pandemic financial trouble of hospitals.

Given that the U.S. has one of the most expensive healthcare systems in the world — and that medtech stock value is ever-increasing — I suggest hospitals tackle the problem by making demands on suppliers, including the ones participating at Heart Rhythm Society, rather than simply pushing the burden to the consumer.

Historically, the conversations at medical technology conferences have been an example of industries essentially talking with themselves. But the pandemic has made these discussions relevant beyond the industry, and their impact is being directly felt by the healthcare consumer. It is time to make healthcare technology costs a matter of public discourse, not simply something we leave to technologists and scientists.

 Lars Thording PhD

Lars Thording, PhD, has a background in academia, consulting and industry leadership. He has been responsible for the launch of numerous market-disrupting solutions across healthcare, insurance and technology. Originally from Denmark, he has taught at universities in Denmark, Ireland and the United States. He currently serves as the vice president of marketing and public affairs at Innovative Health, a medical device reprocessing company specializing in electrophysiology and cardiology technology. Lars currently serves on the board of the Association of Medical Device Reprocessors.

Read more HRS22 conference coverage

 


Related Content

Feature | Cardiovascular Education | Christine Book

February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country ...

Home February 01, 2024
Home
News | Cardiovascular Education

January 15, 2024 — A public-private partnership Think Tank, scheduled for Feb. 29-March 1, will be presented by the ...

Home January 15, 2024
Home
News | Cardiovascular Education

December 4, 2023 — The Minneapolis Heart Institute Foundation (MHIF), an internationally renowned cardiovascular ...

Home December 04, 2023
Home
News | Cardiovascular Education

October 5, 2023 — The 2023 American College of Cardiology (ACC) Quality Summit kicks off on October 11-13 in Orlando ...

Home October 05, 2023
Home
News | Cardiovascular Education

DAIC’s award-winning editorial team delivers industry trends and technology information to the professionals who make ...

Home August 16, 2023
Home
Feature | Cardiovascular Education | Christine Book

May 4, 2023 — A new book on a broad collection of cases, led by a team of investigators from the Smidt Heart Institute ...

Home May 04, 2023
Home
News | Cardiovascular Education

April 10, 2023 — Viatris Inc., a global healthcare company, and the American College of Cardiology (ACC) today released ...

Home April 10, 2023
Home
News | Cardiovascular Education

April 4, 2023 — Harding University has announced it will offer a new degree format for its Master of Science in cardiac ...

Home April 04, 2023
Home
News | Cardiovascular Education

March 30, 2023 — Evermed and the American College of Cardiology (ACC) have announced the launch of ACC Anywhere, a new ...

Home March 30, 2023
Home
News | Cardiovascular Education

December 26, 2022 — Cardiologists, team physicians, certified athletic trainers, advanced practice providers, fellows ...

Home December 26, 2022
Home
Subscribe Now